Crinetics Pharmaceuticals, Inc.·4

Mar 4, 5:43 PM ET

Schilke Tobin 4

4 · Crinetics Pharmaceuticals, Inc. · Filed Mar 4, 2026

Insider Transaction Report

Form 4
Period: 2026-03-03
Schilke Tobin
Chief Financial Officer
Transactions
  • Sale

    Common Stock

    [F1][F2]
    2026-03-03$39.67/sh6,713$266,30578,121 total
Footnotes (2)
  • [F1]Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 10, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.
  • [F2]The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
Signature
/s/ Tobin Schilke|2026-03-04

Documents

1 file
  • 4
    wk-form4_1772664230.xmlPrimary

    FORM 4